BioMarin Pharmaceutical Inc. (BMRN) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

commercial products, and potential future products in different areas of therapeutic research and development. Results may differ materially depending on the progress of Biomarin's product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market, and developments by competitors. And those factors detailed in Biomarin's filings with the Securities and Exchange Commission, such as 10Q, 10K, and 8K reports. In addition, we will use non-GAAP financial metrics as defined in Regulation G during the call today. These non-GAAP measures should not be considered in isolation from, as substitutes for, or superior to financial measures prepared in accordance with U.S. GAAP, and you can find the related reconciliations to U.S. GAAP in the earnings release and earnings presentation, both of which are available in the investor relations section of our website. Please note that our commentary on today's call will focus on non-GAAP financial measures unless otherwise indicated. Beginning on slide three and introducing Biomarin's management team joining today's call, Alexander Hardy, President and Chief Executive Officer, Brian Mueller, Chief Financial Officer, Kristen Hubbard, Chief Commercial Officer, and Greg Freiberg, Chief R&D Officer. I will now turn the call over to Biomarin's President and CEO, Alexander Hardy. Thank you, Tracy. Good afternoon, everyone, and thank you for joining us on today's call. Starting on slide five, I am very pleased with the strong results across the business, leading us to raise full year total revenues guidance at the midpoint and reaffirm our Voxogo revenue outlook for 2025. In addition to top line performance, Biomarin has delivered expanding profitability and significant growth in operating ...